Paper Details

  1. Home
  2. Paper Details

Steroid sparing activity of tenidap in patients with polymyalgia rheumatica: a multicenter double blind randomized placebo controlled study.

Author: BjarnasonD, BryantG, CohenM, EngelbrechtJ, HunderG G, LittmanB H, MertzL, WeaverA

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tenidap was more effective than placebo in controlling symptoms of PMR as prednisone was reduced. 45% of patients receiving tenidap were able to discontinue prednisone without a disease flare compared to 6% for placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine whether tenidap treatment would allow reduction or replacement of systemic corticosteroid treatment in patients with polymyalgia rheumatica (PMR). METHODS: A 15-week double blind, randomized, multicenter, placebo-controlled study of tenidap sodium (120 mg/day) in patients wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7674236

データ提供：米国国立医学図書館（NLM）

Finding Relief from Polymyalgia Rheumatica

This research delves into the world of [Rheumatology], a field that focuses on understanding and treating diseases that affect the joints, muscles, and bones. This study aimed to explore the effectiveness of tenidap in alleviating the symptoms of polymyalgia rheumatica (PMR), a painful condition characterized by stiffness and muscle aches. Using a [double-blind, randomized, multicenter, placebo-controlled study], the researchers investigated whether tenidap could help reduce or replace the need for corticosteroids in patients with PMR.

Tenidap Shows Promise for PMR Management

The study revealed a significant difference between tenidap and placebo groups. As the dosage of prednisone was decreased, patients receiving tenidap experienced better symptom control compared to those receiving placebo. Interestingly, a much higher proportion of patients receiving tenidap (45%) were able to discontinue prednisone without experiencing a disease flare, while only 6% of the placebo group achieved this. This suggests that tenidap has the potential to improve the management of PMR by enabling a more effective reduction in corticosteroid use.

Navigating PMR Treatment: Considerations for Better Health

This study highlights the need to explore alternative treatment options for PMR, as many patients struggle with the side effects of corticosteroids. Tenidap, with its observed efficacy in reducing corticosteroid dependence, offers a promising avenue for improving patient well-being. It is crucial to note that further research is necessary to fully understand the long-term effects and optimal dosage of tenidap in the management of PMR.

Dr.Camel's Conclusion

This research is like a camel caravan traversing the vast expanse of the desert, seeking a more effective path for those suffering from PMR. The study's findings suggest tenidap may offer a smoother journey for patients, potentially reducing the burden of corticosteroid use. However, like a mirage, the true potential of tenidap still needs to be fully explored.

Date :
  1. Date Completed 1995-10-19
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

7674236

DOI: Digital Object Identifier

7674236

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.